TL;DR
Get beauty and skincare favorites delivered free — and shop member deals
- Fast, free delivery on millions of items
- Access to Prime Big Deal Days deals on October 6–7
- Prime Video, Amazon Music and more included
Amorepacific Ventures has made a strategic investment in biotech company Junevity and signed a separate licensing agreement covering cosmetic applications. The companies plan to study skin-ageing pathways using Junevity’s RESET Platform, but have not announced a product, launch date or clinical evidence for cosmetic benefits.
Amorepacific Ventures, the corporate investment arm of the Korean beauty company behind Laneige, has invested in biotechnology firm Junevity and signed a separate licensing agreement covering cosmetic applications. The companies say they will use Junevity’s RESET Platform to investigate skin-ageing pathways that could inform future skin-care products, but they have not announced a product or a timetable for bringing one to market.
The collaboration will combine Junevity’s target-discovery platform with Amorepacific’s expertise in skin biology, cosmetic development and commercialisation. According to the source report, the research will look for pathways that could be relevant to cosmetic uses intended to reset or rejuvenate skin gene networks toward a healthier state. Those descriptions represent the companies’ research aims, not demonstrated effects of a finished product.
The companies have set out distinct roles. Amorepacific will lead development and commercialisation of any cosmetics resulting from the work, while Junevity will continue advancing therapeutic applications of its platform. The investment and licensing agreement are separate parts of the relationship; the source report does not disclose their financial terms or the specific scope of the licence.
Amorepacific R&I Center chief technology officer Brian Byung-Fhy Suh said the research would examine gene networks and transcriptional regulation in skin ageing. Junevity co-founder and chief executive John Hoekman described the deal as a way to explore skin care as a new application for the company’s technology, while continuing its therapeutic research.
A Research Route Into Skin Longevity
The agreement links a biotechnology company’s target-discovery work with a major beauty group’s ability to develop and sell cosmetics. If research identifies pathways that can be translated into suitable cosmetic ingredients or formulations, Amorepacific could use that knowledge to shape future products. For now, however, the announcement concerns research and commercial rights, not a product with established performance or a confirmed launch.
The deal also shows how beauty companies are exploring skin longevity through biological research, including the regulation of genes involved in ageing. That makes the partnership relevant to consumers watching the category, but the phrase “next-generation” is the companies’ characterization of their ambitions. No product-level evidence, consumer results or independent evaluation is provided in the source report.
As an affiliate, we earn on qualifying purchases.
How the Companies Divide the Work
Amorepacific is the parent company of skin-care brand Laneige and operates a corporate venture arm, Amorepacific Ventures. In this arrangement, the investment is paired with a licensing agreement for cosmetic-field applications. The source report does not say whether the licence is exclusive, how long it runs or which markets it covers.
Junevity’s RESET Platform is described as a system for discovering biological targets. The companies plan to apply it to skin-ageing research, while Junevity continues its therapeutic work. Hoekman also referred to the company’s lead siRNA candidate for obesity, which he said was headed into human clinical trials; that programme is separate from the cosmetic collaboration, and the report gives no further trial details.
“The next-generation of skin health innovations will be informed by deeper research-driven insights into the biology of skin ageing, particularly the role of gene networks and transcriptional regulation in longevity.”
— Brian Byung-Fhy Suh, CTO of Amorepacific R&I Center
Product Evidence and Deal Terms
The announcement does not identify any resulting cosmetic product, ingredient, formulation, launch date or retail market. It also gives no investment amount, licensing fee, royalty structure, exclusivity terms or research timeline. The companies have not reported results from the planned skin-ageing research, so it remains unclear which pathways may be identified or whether any findings can be translated into commercially viable cosmetics.
The source describes intended cosmetic applications in terms of resetting or rejuvenating skin gene networks, but provides no clinical data or independent evidence that a future product will achieve those outcomes. Junevity’s obesity candidate is mentioned as part of its separate therapeutic programme; its status should not be taken as evidence for the performance or development stage of the skin-care research.
Research Before Any Product Launch
The next stated step is joint research using Junevity’s RESET Platform and Amorepacific’s skin-science and product-development capabilities. Amorepacific is expected to lead any cosmetic development and commercialisation arising from that work, while Junevity continues therapeutic applications. The companies have not provided dates for research milestones, product decisions or further public updates, so a launch schedule is not yet known.
Readers should look for future disclosures identifying research findings, candidate cosmetic applications and any evidence supporting product claims. Until those details are released, the development is best understood as an investment and research partnership rather than the announcement of a new skin-care treatment or a product ready for sale.
Key Questions
What did Amorepacific invest in?
Amorepacific Ventures made a strategic investment in biotechnology company Junevity. The source report does not state the investment amount.
What will the companies research?
They plan to use Junevity’s RESET Platform to investigate skin-ageing pathways and consider whether findings may support cosmetic applications. No specific pathway or product has been announced.
Is a new skin-care product available?
No product launch was announced. The partnership is focused on research and potential development, and no release date or product details have been provided.
Does the announcement prove the products can rejuvenate skin?
No. The companies describe an intended research direction, but the report provides no product results or clinical evidence supporting rejuvenation claims.
What happens to Junevity’s therapeutic work?
Junevity said it will continue advancing therapeutic applications of its platform. Its lead siRNA candidate for obesity is a separate programme from the cosmetic research, according to CEO John Hoekman.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
